Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets...How License Agreement • November 9th, 2020 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Patent and Know-How License Agreement (“Agreement”) is by and between Mayo Foundation for Medical Education and Research, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (“MAYO”), and Sorrento Therapeutics, Inc. (“SORRENTO”), a for-profit corporation, having a place of business at4955 Directors Place, San Diego, CA 92121, each a “Party”, and collectively “Parties”.
Certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. Such omitted information is indicated by brackets...Exclusive License Agreement • November 9th, 2020 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Agreement is dated July 23, 2020 (the “Effective Date”), and is between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (“Columbia”), and Sorrento Therapeutics, Inc., a Delaware corporation (the “Company”). Columbia and the Company agree as follows:
LICENSE AGREEMENTLicense Agreement • November 9th, 2020 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (this “Agreement”) is made as of July 13, 2020 (the “Effective Date”), by and between Sorrento Therapeutics, Inc., a Delaware corporation (“Sorrento”) and ACEA Therapeutics, Inc., a Cayman Island corporation (“ACEA”). Sorrento and ACEA shall be referred to herein individually as a “Party” and collectively as the “Parties”.
CHANGE OF CONTROL SEVERANCE AGREEMENTChange of Control Severance Agreement • November 9th, 2020 • Sorrento Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
THIS CHANGE OF CONTROL SEVERANCE AGREEMENT (this “Agreement”), dated as of November 5, 2020 (the “Effective Date”), is made by and between Sorrento Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Najjam Asghar (the “Executive”) (collectively referred to herein as the “Parties”).
